MENU

CSL Limited share price tipped to climb to $165

The CSL Limited (ASX: CSL) share price may have risen an impressive 31% since this time last year, but one leading broker believes there could still be plenty more left in the tank.

According to a note out of Citi, its analysts have retained their buy rating and $165.00 price target on the biotherapeutics company’s shares. This price target implies potential upside of almost 13% from the current share price.

What was in the note?

The broker remains bullish on Citi despite news that French pharmaceutical giant Sanofi plans to pay US$11.6 billion to acquire Bioverativ.

Bioverativ, a Biogen Inc. spinoff, is a maker of drugs for haemophilia, one of CSL’s most lucrative revenue streams.

Citi’s analysts don’t believe that there is any danger to CSL in the short to medium term from Sanofi and the acquisition. However, beyond FY 2021 CSL could face disruption if Sanofi’s phase 3 trial of its haemophilia treatment Fitusiran is a success.

Should you buy CSL shares?

I think CSL is one of the highest quality companies on the Australian share market and well worth considering as an investment today.

Over the last 10 years its shares have provided shareholders with an average annual total return of 17.2%, well ahead of the market average. This means that a $25,000 investment in its shares this time a decade ago would now be worth almost $125,000.

While I wouldn’t necessarily expect its shares to generate returns of this magnitude over the next 10 years, I do feel there is a strong chance that its shares will continue to beat the market.

In light of this, I would put CSL up there with fellow healthcare sector shares ResMed Inc. (CHESS) (ASX: RMD) and Ramsay Health Care Limited (ASX: RHC) as a great investment option for investors in 2018.

As well as CSL, here are three more blue chip shares I would class as being must buys todays.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!